ROCHESTER HILLS, Mich. (PRWEB) April 12, 2018
Toxins, pharmaceuticals and many endogenous compounds are metabolized by several classes of enzymes. Oxford has already developed an extensive line of key detoxifying enzymes, including cytochromes P450 and Glutathione-S-Transferases. Uridine diphosphate glucuronosyltransferase (UGT) enzymes also play key roles in the metabolism of drugs and toxins, but few UGTs are commercially available.
Oxford has developed a proprietary method for producing recombinant enzymes in a novel format – a thermostable dry powder that readily hydrates to give a semipermeable catalytic system that is well-tailored to pharmaceutical research. This system exhibits remarkable organic solvent and thermal tolerance along with extended catalysis when compared to traditional recombinant enzymes. This grant will allow Oxford scientists to advance its technology to provide multi-catalytic platform, capable of simultaneous P450 oxidation followed by synergistic glucuronidation. The platform will also include accessory enzymes required to provide the cofactors required for P450 and UGT enzymes – thereby significantly reducing the cost and complexity of glucuronide production.
This research, led by Dr. Enrique Martinez, will give pharmaceutical scientists a robust, easy-to-use system for performing two metabolically-important reactions in one system; P450 oxidation followed by UGT glucuronidation.
Oxford Biomedical Research, Inc. develops, manufactures, and markets products for biomedical research, companion animal veterinary diagnosis and food quality testing.